Your browser is no longer supported. Please, upgrade your browser.
Settings
FBT First Trust NYSE Arca Biotech ETF daily Stock Chart
FBT [NYSE]
First Trust NYSE Arca Biotech ETF
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand- Perf Week0.06%
Market Cap- Forward P/E- EPS next Y- Insider Trans- Shs Float- Perf Month10.69%
Income- PEG- EPS next Q- Inst Own- Short Float- Perf Quarter6.32%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio- Perf Half Y19.52%
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year23.22%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range83.69 - 125.32 Perf YTD36.65%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-0.90% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low48.39% ATR1.56
Employees- Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)61.33 Volatility1.05% 1.30%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.57 Prev Close122.25
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume53.12K Price124.19
Recom- SMA202.36% SMA505.32% SMA20016.50% Volume30,367 Change1.59%
Sep-12-17 01:40PM  Apple Gains As Launch Event Kicks Off; 2 Dividend Plays To Watch Investor's Business Daily
10:36AM  How Gileads Other Products Performed in 2Q17 Market Realist
Sep-11-17 12:55PM  2 Hot Biotech Plays In Reach, But Is Apple Still In Buy Range? Investor's Business Daily
Sep-08-17 02:01PM  Nuplazid Expected to Become a Leading Central Nervous System Drug Market Realist
Sep-06-17 07:37AM  Behind Bioverativs Analyst Recommendations This September Market Realist
Aug-23-17 06:06PM  Ionis Reports Revenue Growth in 2Q17 Market Realist
Aug-22-17 05:29PM  ETF Topper: Biotechnology Isn't Totally on the Outs Barrons.com
Jul-20-17 05:07PM  ETF Topper: Biotech Stocks Break Out Barrons.com
Jul-10-17 12:45PM  The Rise of Amgen Stock in 2Q17 Market Realist
Jul-04-17 10:37AM  What Analysts Recommend for United Therapeutics in June 2017 Market Realist
Jul-03-17 09:01AM  Neurocrine Biosciences: Ingrezza, Collaborations, Ratings Market Realist
Jun-30-17 09:30AM  The Zacks Analyst Blog Highlights: SPDR Technology ETF, SPDR S&P Biotech ETF, First Trust NYSE Arca Biotechnology Index Fund, BioShares Biotechnology Products ETF and SPDR Healthcare ETF Zacks
Jun-29-17 02:33PM  Forget Big Tech, Biotech ETFs are Soaring Higher Zacks
Jun-28-17 04:32PM  Biotech Stocks Are Soaring, Todd Hagopian Leads The Way Forbes
Jun-27-17 04:40PM  ETF Flopper: Biotech Stumbles on Health Care Vote Delay Barrons.com
Jun-22-17 09:03AM  Top Biotech ETFs to Buy Motley Fool
May-15-17 06:00AM  Why Biotech Stocks Are Hitting the Skids Investopedia
Mar-21-17 08:52AM  Ionis Pharmaceuticals Valuation Compared to Its Peers Market Realist
08:52AM  Ionis Pharmaceuticals Valuation Compared to Its Peers
Mar-15-17 08:26AM  Biotech is Bubbling Up
Mar-13-17 05:46PM  Time to Buy Biotech ETFs?
05:46PM  Time to Buy Biotech ETF? Zacks
Feb-28-17 10:38AM  Alnylam Pharmaceuticalss Therapies to Treat hATTR Amyloidosis Market Realist
10:38AM  Alnylam Pharmaceuticalss Therapies to Treat hATTR Amyloidosis
Feb-10-17 08:38AM  Biotech ETFs Powered by Q4 Earnings Zacks
Feb-01-17 09:08AM  Politics Plague Biotech ETFs Investopedia
09:08AM  Politics Plague Biotech ETFs at Investopedia
Jan-27-17 04:30PM  What Lies Ahead for Biotech ETFs in Trump Era? Zacks
Jan-25-17 07:40AM  Here's How to Play the Biotech Rebound TheStreet.com
07:40AM  Here's How to Play the Biotech Rebound
Jan-16-17 10:55AM  Fidelity Biotech Fund: Better than the Index? Motley Fool
10:55AM  Fidelity Biotech Fund: Better than the Index? at Motley Fool
Jan-10-17 06:24AM  Here's Why Merrimack Pharmaceuticals Inc. Fell 47.3% in 2016 Motley Fool
06:24AM  Here's Why Merrimack Pharmaceuticals Inc. Fell 47.3% in 2016 at Motley Fool
Dec-29-16 09:06AM  United Therapeutics: Will RemoSynch Become a Key Growth Driver? Market Realist
09:06AM  United Therapeutics: Will RemoSynch Become a Key Growth Driver?
Dec-06-16 11:57AM  Why TherapeuticsMD Inc. Jumped Today at Motley Fool
Dec-05-16 09:23AM  Is This Why Sarepta Therapeutics Fell 14.5% in November? at Motley Fool
Dec-01-16 11:04AM  How Could Gilead Sciences Restore Its Growth?
09:25AM  Why Neurocrine Biosciences May See Higher Losses in 2016
Nov-14-16 10:57AM  5 Reasons to Buy 5 Low P/E Biotech ETFs
Nov-09-16 02:52PM  Why Arrowhead Pharmaceuticals Inc. Is Plummeting Today at Motley Fool +9.29%
01:04PM  What Drove Regenerons 3Q16 Performance?
Nov-08-16 05:49PM  Why Did Halozyme Therapeutics, Inc. Plunge 29.5% in October? at Motley Fool
03:26PM  Biotech ETFs Slumping on Q3 Results
Nov-02-16 10:05AM  Strensiq: A Potential Driver for Alexion
Oct-27-16 08:34AM  Once Beloved Momentum ETF Loses Its Momo
Oct-20-16 01:57PM  Exclusive: SunTrust Managing Director Shares Thoughts On Drug Pricing, Impact On Biotech
08:06AM  What Are the Drivers behind the Success of Soliris?
Oct-19-16 10:05AM  Why Europe Is an Important Market for Vertexs Orkambi
Sep-29-16 12:04PM  How Regeneron Is Working to Maintain Eyleas Dominance
Sep-27-16 04:05PM  BioMarin to Cross $1 Billion Revenue in 2016
Sep-26-16 07:04PM  Higher Discontinuations Are among Orkambis Concerns
Sep-20-16 02:49PM  How Ionis Pharmaceuticals Valuation Compares to Its Peers
Sep-19-16 02:08PM  Sarepta Stock Surge Boosts Some Biotech ETFs But Not Others at Barrons.com
Sep-14-16 02:19PM  Inside the Recent Surge in Biotech ETFs
Sep-06-16 10:43AM  Technicals, Politics Clash for Biotech ETFs
Sep-05-16 10:04AM  How Is Incytes Only FDA-Approved Drug Performing?
Sep-02-16 10:49AM  Clinton's Proposal To Combat Drug Price Hikes
Aug-31-16 03:39PM  Biotech ETF Industry Outlook
10:58AM  Biotech Leads the Way in Health Care Stocks to Boost 401(k) Returns
10:05AM  United Therapeutics Makes Novel Technologies a Priority
Aug-30-16 09:39AM  Biotech ETFs Back In The Spotlight
Aug-26-16 10:05AM  What Should We Expect from BioMarins Kuvan in 2016?
Aug-25-16 01:04PM  Whats BioMarins Expected Revenue Growth in 2016 and 2017?
Aug-24-16 05:29PM  Did Hillary Clinton's Tweet Cause the Sell-Off in Mylan (MYL) Stock?
09:04AM  How Xtandi Fueled Big Pharmaceutical Interest in Medivation
Aug-16-16 11:30AM  Another Endorsement for Biotech ETFs
Aug-04-16 07:15AM  Biotech Breakout: Take 3
Aug-02-16 05:23PM  Big Biotech Buyout Banter Buoys IBB at Barrons.com
11:06AM  How Much Will BioMarins Kuvan Fetch in 2Q16?
Jul-25-16 11:05AM  Whats behind the Recent Fall in Alexions Valuation Multiple?
Jul-22-16 01:16PM  How Much Will Orkambi Fetch for Vertex Pharmaceuticals in 2Q16?
01:16PM  How Can Alexion Stay ahead of the Competition with Soliris?
Jul-14-16 09:05AM  ALNY Should Complete Revusirans Endeavour Trial Enrollment in Late 2016
Jul-13-16 09:00AM  Biotech ETFs: Will the Once Hot Group Rebound?
Jul-08-16 09:25PM  Inside Alnylam Pharmaceuticalss Analyst Recommendations in 2016
03:03PM  Regeneron in 2Q16: How Much Revenue Growth Could It Have?
Jul-06-16 02:06PM  Inside BioMarins Big Plans for 3Q16
Jun-30-16 06:33PM  Biotechs Building Base?...Or Bursting Bubble?
Jun-29-16 02:24PM  BioMarins Guidance for 2016: The Inside Story
Jun-23-16 04:55PM  As Cost Panel Gets Delayed, Buy These 3 Biotech ETFs
Jun-21-16 10:30AM  Expect More Election Year Volatility For Biotech ETFs
Jun-07-16 12:33AM  Biotech Bounce: Sizzle Or Fizzle?
Jun-06-16 08:00AM  A Catalyst for Biotech ETFs
Jun-03-16 08:00AM  Trying to Believe in Biotech ETFs
Jun-01-16 08:30AM  Finally A Biotech ETF Bounce?
May-27-16 11:37AM  Government Study: Cellphone Radiation Linked To Cancer
May-26-16 05:30AM  10 Best Performing ETFs Year To Date
May-17-16 11:40AM  Biotech ETFs Soar on Pfizer-Anacor Deal: SBIO, XBI in Lead
May-16-16 10:07AM  Deals Boost Niche, Equal-Weighted ETFs at Barrons.com
08:00AM  Resisting the Temptation of Biotech ETFs
May-13-16 06:07PM  Medivation Is for Sale: How Much Should It Get?
06:06PM  How Can Regeneron Pharmaceuticals Boost Revenue from Praluent?
04:48PM  What Lies Ahead for Biotech ETFs?
May-04-16 09:07AM  A Look at Vertexs Cystic Fibrosis Patient Opportunity
May-03-16 05:49PM  Understanding Alexions Share Price Performance since Its Previous Earnings
May-02-16 03:22PM  Biotech ETFs Sink on Mixed Q1 Results
12:49PM  Hit The Lab With These 17 Biotech ETFs
Apr-30-16 01:05AM  Seattle Genetics Valuation: How Does It Compare? Market Realist
The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology IndexSM. The fund will normally invest at least 90% of its net assets (including investment borrowings) in common stocks that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. It is non-diversified.